Paul Nakagaki, Ph.D

Head of Group Research Strategy
F. Hoffmann-La Roche Ltd
Basel, Switzerland

Paul Nakagaki recently returned to Roche Group Research Strategy from a six-month sabbatical at the Institute for OneWorld Health, a non-profit pharmaceutical company located in San Francisco, California. There, he worked with the founders, the CEO and the executive leadership team on the corporate strategy. Prior to his stint with OneWorld Health, he was the Head of the Pharma in 2015 Project Office reporting to William Burns, CEO of the Pharmaceutical Division. Pharma in 2015 was initiated in late 2005, and focused on the creation of the new R&D model that will provide sustainable innovation and productivity for Roche Pharma. Paul has been working on R&D strategies supporting the corporate Winning for the Future agenda since 2001. Until July 2007, Paul was Head of Pharma Research Strategy reporting to Dr. Jonathan Knowles, President of Roche Research, a position he held since 1999. In this capacity, he was responsible for establishing and implementing the Research strategy and Research portfolio strategy.

Philippe Farabolini

Dir of Business Development & Head of the Tuberculosis Program in "Access to Medicines" dept, Sanofi-aventis

Philippe Farabolini performed his entire career within the sanofi-aventis group. He graduated as an Agricultural Engineer and obtained a Master's degree in Marketing and Management at the HEC Paris School of Business. He joined Sanofi in 1987, leading various projects in sales, marketing and business development within the Animal Health subsidiary. In 1995, he joined Sanofi's Pharmaceutical Division as Director for North Africa. Following the 1999 Sanofi-Synthelabo merger, he moved to Morocco where he leaded Group Operations & Partnerships for establishment of collaborations with third parties. He came back to France in 2003, when he was involved in the elaboration of the strategy and the full implementation of the "Access to Medicines" program, committed to improve Access to Medicines for unprivileged populations in developing and emerging countries. He is Director of Business Development and Head of the Tuberculosis Program in "Access to Medicines" department since 2006.

David P. Perry

Chief Executive Officer,
Anacor Pharmaceuticals, Inc.

David P. Perry, has served as Anacor's President and Chief Executive Officer since March 2002 and has been a member of the board of directors since April 2002. In 1997, Mr. Perry founded Chemdex Corporation, which was acquired by NexPrise, Inc., a business-to-business marketplace company that focused on the life-sciences industry, and until November 2001 served as its Chief Executive Officer. In 1995, Mr. Perry co-founded Virogen, a biotech company based in Boston. Mr. Perry has a B.S. from the University of Tulsa and an M.B.A. from Harvard Business School.

Nina Grove, M.A., MPH

Vice President, Strategic Program Development, iOWH

Ms. Grove joined iOWH in February 2006, bringing over 25 years of biopharmaceutical product development experience in all aspects of drug development. Nina currently leads the malaria program at OneWorld Health and has recently focused on access and delivery strategies for several programs. During over 20 years at Genentech, Inc., Nina held positions in Quality Control, Product Operations, Product Development, and as Director of Commercial Regulatory Affairs where she was responsible for the product launch of four new drugs for asthma, cancer, and psoriasis. In addition to team leadership and project management roles for international drug and vaccine development and information technology implementations, she also served on several key committees and established a program management office. Prior to joining Genentech, Nina performed laboratory research both at the University of California, Berkeley, and at Stanford University. Nina earned her BA in Biology from the University of California at Santa Cruz and Masters degrees in Medical Microbiology and Public Health from the University of California, Berkeley.

Notes

Bio 2009 Breakout Sessions

Sponsored by iOWH and DNDi

Photo Courtesy of Jonathan Torgovnik. All Rights Reserved.

I. PDPs and Alternative IP Management/Tech Transfer Strategies for Improved Global Health

PDPs are becoming important contributors in the global public health community by developing essential tools to support disease control efforts. To achieve their goals and ensure their development activities, PDPs rely both on publicly available and patented technologies developed by both the public and private sector. A great challenge for PDPs is to access patented technologies under conditions ensuring product affordability and accessibility to neglected patients, while preserving the interests of patent holders. This panel will discuss the structuring of deals -through the perspective of IP management and access to knowledge- which can accommodate the apparently divergent interests of global health non-profit organizations and their private and public sector partners, and provide examples of successful licensing strategies.

Moderator: Mervyn Turner

Panelists: Julie Cheng, Carol Mimura, Patrick Nef, and Gerald Siuta

II. Different Types of Partnerships Which Compose PDPs for Improved Global Health.

This panel discussion explores the product development relationships and their complexities and how those various companies work together for improved global health. Led by moderator Paul Nakagaki (Roche), the panelists include representatives from non-profit organizations such as the Institute for OneWorld Health and DNDi, a French pharmaceutical Sanofi-Aventis, and biotechnology company Anacor.

Moderator: Paul Nakagaki

Panelists: Philippe Farabolini, Nina Grove, Jean-Pierre Paccaud and David Perry

DNDi

Drugs for Neglected Diseases *initiative*

The Drugs for Neglected Diseases initiative (DNDi) is an independent, not-for-profit product development partnership, working to research and develop new and improved treatments for neglected diseases such as leishmaniasis, human African trypanosomiasis or sleeping sickness, Chagas disease, and malaria. DNDi was founded in 2003 by five public research institutions along with the humanitarian organization Médecins Sans Frontières (MSF). With the objective to address unmet patient needs for these diseases, DNDi has developed the largest ever R&D portfolio for the kinetoplastid diseases and has already released two new antimalarial treatments. In 2007, DNDi launched ASAQ, a fixed-dose antimalarial, with sanofi-aventis. In 2008, DNDi and Farmanguinhos (Brazil) made available ASMQ, DNDi's second fixed-dose antimalarial. A new, improved treatment for sleeping sickness, the first in twenty years, has just been added to the WHO Essential Medicines List, after promising clinical results from a pivotal phase III study coordinated by DNDi, Epicentre, and MSF. Learn more at www.dndi.org.

Jean-Pierre Paccaud, Ph.D

Business Development Director, DNDi

Dr. Paccaud is responsible for DNDi's business development activities, including opportunity identification, contract structure and negotiations, and alliance management. Prior to joining DNDi, he served as Head of Business Development for R&D products at OM Pharma. Dr. Paccaud also notably founded and led Athelas SA, a startup company active in the field of anti-bacterial drug discovery, until its merger with Merlion Pharmaceuticals. Before taking on entrepreneurial challenges in industry, Dr. Paccaud spent more than 15 years in academia, working in immunology, diabetes, and cell biology, heading a research group as a faculty member at the University of Geneva School of Medicine. Jean-Pierre Paccaud completed his post-doctoral studies at the University of California at Berkeley, and earned his PhD at the University of Geneva.

iOWH

Institute for OneWorld Health

The Institute for OneWorld Health develops safe, effective, and affordable new medicines for people with infectious diseases in the developing world. Founded in 2000, the Institute for OneWorld Health (iOWH) is the first non-profit pharmaceutical company in the US. It was founded to address the wide gulf between human need, scientific effort, and the marketplace. In the spirit of partnership and collaboration, iOWH capitalizes on the specific talents and resources that our partners bring to this essential scientific endeavor. The Institute for OneWorld Health is headquartered in San Francisco, California with a field operation office in Bihar, India. We currently have three active drug development programs, developing medicines to treat visceral leishmaniasis, malaria and diarrheal diseases.

Julie Cheng, Esq.

General Counsel & Vice President
Business Development, iOWH

Julie Cheng oversees all of iOWH legal matters and is responsible for business development including setting up key partnerships among iOWH, academia and pharmaceutical companies in different disease areas. Her legal experience has primarily been in the corporate world, including working at the FMC Corporation and Alcon Laboratories Inc. Prior to joining iOWH she spent almost seven years with Bayer HealthCare with her most recent position being Asst. General Counsel. Before that she worked in Philadelphia for Rohm and Haas Company, focusing on international intellectual property. Julie has participated on the board of the Public Interest Law Center of Philadelphia (PILCOP) and worked with Big Brothers Big Sisters, Philadelphia Volunteer Lawyers for the Arts, the West Texas Legal Services, and the AIDS Outreach Center. She is also involved with the National Asian Pacific American Bar Association (NAPABA) and local Asian Pacific American bar associations. . Julie received her B.A. from Reed College and her J.D. from Franklin Pierce Law Center.

Mervyn J. Turner, Ph.D

Chief Strategy Officer, Merck & Co., Inc., and Senior VP, Worldwide Licensing & External Research, Merck Research Laboratories

Dr. Mervyn Turner joined Merck Research Laboratories in 1985. Over the last 24 years, he has held many positions of increasing responsibility at Merck. In August 1999, Dr. Turner was appointed Senior VP, Merck Frosst Centre for Therapeutic Research in Montreal, Canada. Dr. Turner returned from his assignment in Montreal in October 2002 to take up his current position as Senior Vice President, Worldwide Licensing and External Research. In this role, he is responsible for the oversight of all of Merck's licensing activities, and for the management of academic relations. Most recently, Dr. Turner has also been appointed to the newly created role of Chief Strategy Officer for Merck & Co. Inc. where he leads the formulation and execution of Merck's long term strategic plan and the linkage of that strategy to the business plans of Merck's Franchises, Divisions, and Functions.

Professor Patrick Nef, Ph.D

Adjunct Professor,
Rockefeller University

Prof. Patrick Nef has held several executive positions within pharmaceutical and biotech industry: first at F. Hoffmann-La Roche in Basel as Vice-Director preclinical CNS research, then as Director of Partnering and Licensing; subsequently he became CEO, CSO, CBO and consultant of several biotech companies in both the US and EU (Faust Pharmaceuticals, Xytis Inc., Synosia Therapeutics, Polyphor AG, Debiopharm, BioXpress Therapeutics). Patrick holds a PhD from the University of Geneva in biochemistry/neurobiology. He was Assistant Professor in the Biochemistry department of the University of Geneva from 1992 to 1998. He has published over 40 papers and reviews and is currently adjunct professor at the Rockefeller University, NY in the laboratory of Nobel Laureate Professor Paul Greengard.

Gerry Siuta, Ph.D

President, Siuta Consulting

Dr. Siuta is the President of Siuta Consulting, Inc., a pharmaceutical licensing consulting firm that he established in 1995 to provide worldwide in- and out-licensing services to pharmaceutical companies, biotechnology companies, universities and research institutes. As consultant to the Global Alliance for TB Drug Development (TB Alliance) since 2001, he has negotiated Agreements with the Institute of Materia Medica in China, Bayer HealthCare, GlaxoSmithKline, Chiron Corporation, the Korea Research Institute of Chemical Technology and the University of Auckland in New Zealand. Prior to starting his consulting business, Dr. Siuta spent 20 years in the pharmaceutical industry with American Cyanamid Company. Dr. Siuta received his B.A. in Chemistry from Hunter College of The City University of New York and his Ph.D. in Organic Chemistry from Fordham University. He is a member of the Licensing Executives Society (LES) and the Association of University Technology Managers (AUTM).

Carol Mimura

Assistant Vice Chancellor for Intellectual Property and Industry Research Alliances, UC Berkeley

Carol Mimura is the Assistant Vice Chancellor for Intellectual Property & Industry Research Alliances (IPIRA) at the University of California, Berkeley. IPIRA is the portal to Berkeley for industry access to Berkeley's preeminent faculty and research capabilities. Carol has a B.S. degree from Yale University in Molecular Biophysics & Biochemistry and Ph.D. in biology (biochemistry and microbiology concentration) from Boston University. She was an NIH-sponsored postdoctoral fellow and research scientist at U.C. Berkeley in Biochemistry and in Chemical Biodynamics. She serves on the Drug Forum of the National Academies of Sciences Institute of Medicine, has served on the board of directors of the Children's Hospital Research Institute in Oakland, CA and as a board member (the Chancellor's alternate) of BayBio, the regional voice of biotechnology in Northern California. She was a former Executive Director of U.C. Berkeley's Office of Technology Licensing.

Notes